Effect of Saroglitazar, a Dual PPAR α/γ Agonist, on the Serum Lipid Profile in Patients With Non-Cirrhotic NAFLD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis
Clin. Gastroenterol. Hepatol. 2023 Sep 01;21(10)2597-2605.e2, MS Siddiqui, D Parmar, F Sheikh, SK Sarin, L Cisneros, S Gawrieh, T Momin, A Duseja, AJ SanyalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.